ACT Genomics and mProbe Announce Strategic Partnership to Advance Precision Medicine in Asia

Taipei,Taiwan, October 24, 2024 — ACT Genomics Co. Limited, aleader in precision diagnostics and clinical testing, and mProbe Taiwan Inc., apioneer in proteomics technology for precision health, have signed a Memorandumof Understanding (MOU) to collaborate on advancing precision medicine acrossAsia. The agreement aims to combine the unique expertise of both companies toprovide cutting-edge diagnostic solutions to healthcare providers in theregion.

Underthe terms of the MOU, ACT Genomics will act as the strategic distributor for mProbe'sinnovative OncoOmicsDx-30PRO and OncoOmicsDx-72PRO products in several Asianmarkets, including Taiwan, Hong Kong, Macau, Singapore, Thailand, Malaysia, andIndonesia. This collaboration will focus on market development, sales, andpromotional activities aimed at expanding access to mProbe’s advancedproteomics technology for oncology diagnostics.

"We are honored to partner with mProbe to bring theirtransformative proteomics technology to complete the diagnostic aspects" said Dr. HuaChien Chen, Chief Scientific Officer & Co-Founder of ACT Genomics. "This partnership aligns with our commitment to providinghigh-quality, precise diagnostic tools that empower clinicians to deliverpersonalized treatment plans."

mProbe’sproprietary proteomics-based products, OncoOmicsDx-30PRO and OncoOmicsDx-72PRO,are designed to assist in oncology diagnostics by offering detailed proteomicprofiling. The collaboration also opens the door to potential future technologytransfers and further integration of proteomics into clinical practices acrossthe region.

"Our goal at mProbe is to transform healthcare throughprecision medicine," said Peter Chen, CEO of mProbe."By partnering with ACT Genomics, we are confidentthat we can accelerate the adoption of our proteomics technology across Asia,ultimately improving patient outcomes in the fight against cancer."

TheMOU marks the beginning of a strategic partnership aimed at leveraging bothcompanies’ expertise to address the growing demand for precision medicine inoncology. With ACT Genomics’ established distribution network and marketknowledge, and mProbe’s innovative diagnostic solutions, the collaboration isexpected to make a significant impact on cancer diagnostics and treatment inthe region.

AboutACT Genomics

ACTGenomics is a world-leading genomic test solution provider. Our mission is tomake personalized medicine accessible to all. ACT Genomics offers precisionmedicine services globally. Combining tumor biology, cancer genomics, andbioinformatics experts to provide treatment guidelines for solid tumors,relapse, and drug resistance, as well as cancer monitoring, risk assessment,and immunotherapy evaluation. ACT Genomics is dedicated to turning every cancerpatient's genetic information into actionable resolutions through cutting-edgenext-generation sequencing (NGS) platforms, bioinformatics analysis, andcomprehensive service offerings.

www.actgenomics.com

AboutmProbe

mProbeinnovation originated from Stanford University and has a CAP/CLIA-certifiedclinical mass spectrometry laboratory in Maryland, USA. mProbe believes thatthe future is personalized medicine. Only by fully understanding the biology ofa patient’s cancer can you determine the optimal treatment for that patientand, more to the point, their unique cancer. When an oncologist has access toproteomic and genomic data from FFPE tissue samples, they receive an additionaland invaluable profile of the cancer at the molecular level. This allows thedoctor to tailor the treatment directly to the cancer. This technology has beenaccepted by Medicare insurance, a national health insurance program in theUnited States.

www.mprobe.com

Formedia inquiries, please contact:

ACT Genomics: pr@actgenomics.com

mProbe: mprobe.tw@mprobe.com

‍